Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $11.53.
Several equities research analysts recently commented on LUNG shares. Canaccord Genuity Group decreased their target price on Pulmonx from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Jefferies Financial Group began coverage on shares of Pulmonx in a research note on Monday, March 10th. They set a "buy" rating on the stock. Piper Sandler reaffirmed an "overweight" rating and issued a $9.00 price target (down from $10.00) on shares of Pulmonx in a research note on Thursday, May 1st. D. Boral Capital restated a "buy" rating and issued a $17.00 target price on shares of Pulmonx in a research note on Thursday, May 1st. Finally, Morgan Stanley started coverage on Pulmonx in a research note on Monday, March 10th. They set an "equal weight" rating on the stock.
Check Out Our Latest Stock Analysis on LUNG
Insider Buying and Selling at Pulmonx
In other Pulmonx news, Director Richard Ferrari sold 8,000 shares of Pulmonx stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $3.16, for a total value of $25,280.00. Following the sale, the director owned 87,024 shares of the company's stock, valued at approximately $274,995.84. The trade was a 8.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel David Aaron Lehman sold 10,457 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $3.13, for a total transaction of $32,730.41. Following the transaction, the general counsel directly owned 273,039 shares of the company's stock, valued at $854,612.07. This represents a 3.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 43,388 shares of company stock valued at $136,044 in the last ninety days. 6.80% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new position in shares of Pulmonx in the fourth quarter worth about $43,000. ProShare Advisors LLC bought a new stake in Pulmonx during the 4th quarter valued at $72,000. Stifel Financial Corp purchased a new stake in shares of Pulmonx during the fourth quarter worth $81,000. Vontobel Holding Ltd. bought a new position in shares of Pulmonx in the first quarter worth $82,000. Finally, Graham Capital Management L.P. raised its stake in shares of Pulmonx by 73.3% during the 4th quarter. Graham Capital Management L.P. now owns 18,071 shares of the company's stock valued at $123,000 after purchasing an additional 7,641 shares during the period. Institutional investors own 91.04% of the company's stock.
Pulmonx Trading Down 5.0%
Shares of Pulmonx stock traded down $0.14 during midday trading on Friday, reaching $2.64. The company had a trading volume of 214,856 shares, compared to its average volume of 305,265. The stock has a fifty day moving average price of $3.23 and a 200 day moving average price of $5.46. Pulmonx has a fifty-two week low of $2.50 and a fifty-two week high of $9.37. The firm has a market cap of $106.29 million, a PE ratio of -1.83 and a beta of 0.45. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.97 and a quick ratio of 4.29.
Pulmonx (NASDAQ:LUNG - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.01. Pulmonx had a negative net margin of 65.27% and a negative return on equity of 63.69%. The company had revenue of $22.54 million for the quarter, compared to analyst estimates of $22.03 million. On average, equities analysts anticipate that Pulmonx will post -1.55 earnings per share for the current year.
About Pulmonx
(
Get Free ReportPulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Further Reading
Before you consider Pulmonx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulmonx wasn't on the list.
While Pulmonx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
